yes it has potential to be a commercially successful drug IMO, and I forsee practices testing viral syndromes for RSV along w covid more since the pandemic especially once effective medicines are around, but I still think covid is more market moving for ENTA than RSV, so a more disproportionate number of eggs in that basket IMO (and obviously hopeful for good outcome - it is a PI ENTA has good track record w PI etc, but jsut saying
Market Data 
Markets 
AI
